Why Every Major Pharmacy Now Covers Eli Lilly’s Obesity Drugs
The Coverage Reversal Nobody Saw Coming
A year ago, CVS Caremark made a bet on Novo Nordisk. Eli Lilly obesity treatments were not the pharmacy benefit manager’s preferred pick at the time — the pharmacy benefit manager gave Wegovy preferred placement over Eli Lilly’s Zepbound, a move that rattled analysts and stirred talk of an outright price war between the two obesity-drug giants. It looked, at the time, like a signal that insurers could dictate the winner in the biggest new drug category in decades.
That bet has now unwound. As of mid-2026, all three major U.S. pharmacy benefit managers cover Eli Lilly’s full obesity portfolio, including Foundayo, its new daily oral GLP-1 pill. The reversal is not a small correction. It is an admission, from the companies whose entire job is steering prescription volume toward the cheaper or better-rebated option, that patients and physicians were not following the script CVS Caremark had written for them.
Eli Lilly obesity treatments did not win this fight on paper. They won it in exam rooms, refill records, and the kind of quiet, repeated patient preference that eventually forces a benefit manager’s hand regardless of what a rebate contract says.
Why This Story Surfaced Now
The renewed attention traces to Baron Capital’s second-quarter 2026 investor letter for its Health Care Fund, which singled out Eli Lilly as a standout contributor to performance. The fund’s managers pointed specifically to the pharmacy benefit manager reversal and to fresh clinical trial data as reasons for their confidence. Eli Lilly shares closed at $1,121.36 on August 3, 2026, giving the company a market capitalization of roughly $1.06 trillion, even after a rough one-month stretch that saw the stock fall 9.24%.
That single-month dip sits oddly next to a 46.40% gain over the trailing 52 weeks — a reminder that even the market’s most confident growth story moves in fits and starts, not a straight line.
What Foundayo Changes
To understand why the pharmacy benefit manager reversal matters, it helps to understand what Foundayo is competing against. Zepbound and Wegovy are injectable GLP-1 drugs — effective, but requiring a needle, refrigeration logistics, and a level of routine that not every patient tolerates well. An oral daily GLP-1 removes the single biggest point of friction in the category: the injection itself.
This is not a cosmetic difference. Adherence is the quiet killer of chronic-disease treatment. A pill that a patient takes with breakfast is mechanically easier to stick with than a weekly injection that requires storage planning and a needle. If Foundayo holds up commercially the way early coverage decisions suggest, it does not just add a product to Eli Lilly’s obesity lineup — it removes the main excuse patients have had for stopping treatment.
For a pharmacy benefit manager, that adherence math matters as much as the sticker price. A cheaper drug that patients quietly abandon after two months costs the health system more in the long run than a pricier one they actually keep taking. That is the calculation CVS Caremark appears to have run headfirst into.
The Pipeline Behind the Headline Drug
Foundayo’s coverage win is the visible part of the story. The less visible part, and arguably the more important one for Eli Lilly’s next five years, is what is still in clinical trials. Phase 3 data on retatrutide showed weight loss in the high-20% range at higher doses, and close to 20% at lower doses, with what investors and researchers characterized as strong tolerability.
Those are not incremental numbers. Weight-loss results in that range put retatrutide in a different tier than most currently marketed obesity treatments, GLP-1 drugs included. A therapy that can deliver that scale of results while patients stay on it is the kind of data point that reshapes a category rather than simply adding a competitor to it.
Behind that sits eloralintide, a compound in earlier-stage Phase 2 testing. Early results reportedly showed efficacy and tolerability comparable to Zepbound, and combination-therapy data — pairing eloralintide with other compounds in Lilly’s pipeline — is expected soon. If that combination data lands well, Eli Lilly would have not one flagship obesity drug but a layered portfolio: an oral option for adherence, an injectable incumbent for proven results, and next-generation compounds pushing the ceiling on how much weight loss is achievable.
The mechanism worth sitting with here is not any single drug. It is that Eli Lilly is running its obesity business the way a technology company runs a product roadmap — shipping a strong version now while a materially better version is already in trials behind it. Competitors are left playing catch-up against the second generation while manufacturers are the ones still finalizing the current one.
A Market Big Enough to Reward Being Second, Too
Baron Capital’s letter puts a number on where this is headed: a category the fund believes can exceed $150 billion. That figure deserves a pause, because it changes the competitive calculus most observers default to. In a market that size, being the clear market leader — which Eli Lilly’s portfolio increasingly appears to be — does not require crushing every competitor. Novo Nordisk can remain a large, profitable company in obesity drugs and Eli Lilly can still be the dominant one. Both things are true simultaneously in a market this large.
This is the part of the obesity-drug story that gets flattened into a simple rivalry narrative when it is actually closer to a rising tide with an unmistakable current. Wegovy’s early head start and CVS Caremark’s initial preferred placement suggested Novo Nordisk might lock in structural advantages before Lilly could respond. The last year suggests the opposite: that in a market driven this heavily by patient demand and physician preference, distribution advantages built on rebate contracts erode quickly once the clinical and adherence data diverges.
What This Means Beyond One Company’s Stock
Eli Lilly’s position here is a useful case study in something broader than obesity medicine: how quickly a benefit-management structure built to control costs can be overridden by demand it did not anticipate. CVS Caremark’s original Wegovy preference was a rational bet based on the information available at the time. It did not fail because the reasoning was bad. It failed because patient and physician behavior did not follow the incentive structure the contract assumed.
That has a lesson for anyone watching how insurers, employers, and benefit managers try to steer choice in high-cost drug categories generally — not just obesity treatment. Coverage decisions are not the finish line. They are an opening bid in a negotiation that patients and doctors continue to influence long after the ink dries, through the prescriptions they actually request and the refills they actually pick up.
For investors, the practical takeaway sits closer to the Baron letter’s own framing: strong stock selection in pharmaceuticals and biotechnology drove outperformance this quarter, while limited exposure to managed care names held returns back. Eli Lilly’s obesity portfolio was one name doing the heavy lifting, but the fund’s broader thesis — improving biotech funding, recovering managed care margins, and demand growth tied to an aging population and chronic disease — describes a sector-wide tailwind, not a single-company story.
An Active Lawsuit With Novo Nordisk Persists
None of this commercial momentum has erased the legal tension between the two companies. Eli Lilly and Novo Nordisk remain in an active dispute, one prominent enough that market commentators, including Jim Cramer, have weighed in publicly on how it might play out. Litigation of that kind rarely resolves quickly, and it adds a layer of uncertainty that coverage wins and trial data alone do not remove.
It is worth remembering that commercial execution and legal standing are separate battles. Eli Lilly can keep winning pharmacy benefit manager coverage and posting strong pipeline data while a courtroom outcome still has the power to reshape how either company can market or price its products down the line. Investors weighing the obesity-drug category need to hold both realities at once rather than assuming one guarantees the other.
A $150 Billion Market Still Untested at Scale
The open question is not whether Eli Lilly’s obesity drugs work — the clinical data on that point is well established. It is whether a market projected to exceed $150 billion can scale its manufacturing, distribution, and long-term safety monitoring at the pace demand is asking for. Drugs that reshape how millions of people manage a chronic condition invite scrutiny that a decade of steady prescriptions has not yet fully tested.
What is clear from where things stand now is this: a pharmacy benefit manager built its strategy around steering patients toward one company’s drug, and within a year, patient and physician preference pushed all three major benefit managers to reverse course. That is not a marketing win. It is a signal about where the actual leverage in this market sits — and it is not with the people writing the coverage contracts.
WiiM Mini Review: Hi-Res Streaming for Any Stereo
This product may be useful for you: WiiM Mini review: verified buyer analysis of AirPlay 2, sound quality, setup, reliability, and who it suits best
As an Amazon Associate, TruePickUS can earn from qualifying purchases.
FAQ
What is Foundayo and how is it different from Zepbound?
Foundayo is Eli Lilly’s daily oral GLP-1 medication for obesity, while Zepbound is an injectable GLP-1 treatment. The oral format removes the need for injections, which can make it easier for some patients to stick with treatment long-term.
Why did CVS Caremark switch its preferred obesity drug coverage?
CVS Caremark originally gave Wegovy preferred coverage, but as of 2026 all three major pharmacy benefit managers, including CVS Caremark, cover Eli Lilly’s obesity portfolio. The shift followed sustained patient and physician demand for Lilly’s drugs, including Zepbound and Foundayo.
How big is the obesity drug market expected to become?
Baron Capital’s Q2 2026 investor letter estimated the obesity drug category could exceed $150 billion, driven by strong demand, an aging population, and rising chronic disease rates.
What is retatrutide and how effective is it in trials?
Retatrutide is an experimental drug in Eli Lilly’s obesity pipeline. Phase 3 data showed weight loss in the high-20% range at higher doses and nearly 20% at lower doses, with strong tolerability reported.
Is Eli Lilly still in a legal dispute with Novo Nordisk?
Yes, Eli Lilly and Novo Nordisk have an ongoing legal dispute that has drawn public commentary from market analysts, separate from the companies’ commercial competition in the obesity drug market.
Related Reading
- Eli Lilly Acquisitions — How Pharma’s Biggest Company Spends Its Billions
- TrumpRx Launches to Lower Prescription Drug Costs for Americans
Official Source Links
For further reading and verification:
